Search Results: Zolgensma
Updated SMA Drug Pipeline Now Available
We’ve recently released an update to the SMA drug pipeline. This latest version includes: 23 active programs, including two approved therapies. 15 pharmaceutical partners. 6 […]
Family Friendly Research Poster Session Presenters Announced
The Family Friendly Research Poster Session will be held on Saturday, June 29th from 6:30pm to 8:00pm at the 2019 Annual SMA Conference. The Family […]
Cure SMA and Parent Project Muscular Dystrophy Announce Collaboration
Today, Cure SMA and Parent Project Muscular Dystrophy (PPMD) announced their strategic collaboration to collect real-world data to improve the lives of those affected by […]
Cure SMA Advocates for SMA Community at ICER Hearing
On Thursday, March 7, Cure SMA testified on behalf of the SMA community at a meeting of the Institute for Clinical and Economic Review (ICER). […]
Fall 2018 Issue of Directions Now Available
The Fall 2018 issue of Directions is now available online. Please visit our Support & Care Publications page to download this issue or past issues […]
December Webinar on SMA Treatments and Clinical Trials Now Available Online
A recording of the December 13th webinar updating the community on SMA treatments and clinical trials is now available online. A PDF of the webinar […]
Advocacy Year-in-Review 2018
For Cure SMA, 2018 has been a year of great progress. As we continue to make strides into 2019, it is important to take a […]
AveXis Issues Community Statement on BLA Acceptance
AveXis has provided the following community statement on the BLA submission and acceptance for their investigational therapy, AVXS-101 – now known as ZOLGENSMA®. Dear SMA […]
Novartis Announces FDA Filing Acceptance and Priority Review for AVXS-101
Novartis today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for AVXS-101, now known as ZOLGENSMA® […]
- « Previous
- 1
- …
- 5
- 6
- 7